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Abstract
Objective: To determine the effectiveness of erenumab in treating headaches in idi-
opathic intracranial hypertension (IIH) in whom papilledema had resolved.
Background: Disability in IIH is predominantly driven by debilitating headaches with 
no evidence for the use of preventative therapies. Headache therapy in IIH is an ur-
gent unmet need.
Methods: A prospective, open-label study in the United Kingdom was conducted. 
Adult females with confirmed diagnosis of IIH now in ocular remission (papilledema 
resolved) with chronic headaches (≥15 days a month) and failure of ≥3 preventative 
medications received erenumab 4-weekly (assessments were 3-monthly). The pri-
mary end point was change in monthly moderate/severe headache days (MmsHD) 
from baseline (30-day pretreatment period) compared to 12 months.
Results: Fifty-five patients, mean (SD) age 35.3 (9) years and mean duration of head-
aches 10.4 (8.4) years with 3.7 (0.9) preventative treatment failures, were enrolled. 
Mean baseline MmsHD was 16.1 (4.7) and total monthly headache days (MHD) was 
(29) 2.3. MmsHD reduced substantially at 12 months by mean (SD) [95% CI] 10.8 (4.0) 
[9.5, 11.9], p < 0.001 and MHD reduced by 13.0 (9.5) [10.2, 15.7], p < 0.001. Crystal 
clear days (days without any head pain) increased by 13.1 (9.5) [9.6, 15.3], p < 0.001, 
headache severity (scale 0–10) fell by 1.3 (1.7) [0.9, 1.9], p < 0.001, and monthly an-
algesic days reduced by 4.3 (9.2) [1.6, 6.9], p = 0.002. All these measures had im-
proved significantly by 3 months, with a consistent significant response to 12 months. 
Headache impact test-6 score and quality of life Short Form-36 Health Survey signifi-
cantly improved at 12 months. Sensitivity analysis revealed similar results for patients 
with and without a prior migraine diagnosis (28/55 (52%) patients) or those with or 
without medication overuse (27/55 (48%) patients).
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INTRODUC TION
Idiopathic intracranial hypertension (IIH) is a chronic disease char-
acterized by raised intracranial pressure (ICP) often associated 
with younger age, obesity, and females.1,2 Disability in IIH is pre-
dominantly driven by debilitating headaches that significantly im-
pact quality of life.3,4 Reduction in ICP can improve headaches in 
IIH,5,6 but headaches often persist despite normalization of ICP.4,7–9 
Patients with prior IIH with resolved papilledema are termed “IIH 
in ocular remission” and frequently have a high long-term headache 
morbidity.1 Headaches in IIH typically have migraine-like charac-
teristics (approximately 80%).8 There is no evidence for the use 
of headache preventative therapies for IIH headache with limited 
choices due to the risk of weight gain or mood disorders.10
The incidence of IIH is increasing markedly (350% increase in 
10 years) with increased economic burden as headaches drive fre-
quent presentations to hospitals.11,12 Headache therapy is conse-
quently an urgent unmet need in IIH.13
Calcitonin gene-related peptide (CGRP) is implicated in migraine 
etiology with elevated levels noted during migraine attacks, levels 
normalizing after therapeutic triptan administration, and exoge-
nous administration of CGRP precipitating migraine-like headache 
in migraineurs.14–17 Monoclonal antibodies targeting the CGRP sig-
naling pathway are efficacious and well-tolerated therapies for both 
episodic and chronic migraine and are currently licensed for treat-
ment.18–24 Data are emerging supporting the role of CGRP in post-
traumatic headache.25 We hypothesized that CGRP would also have 
a role in driving IIH headaches.
This open-label prospective evaluation aimed to determine the 
effectiveness of erenumab in treating headaches in patients with IIH 
in ocular remission (resolved papilledema).
METHODS
This study was approved and registered at University Hospitals 
Birmingham National Health Service Foundation Trust (UHB NHS 
FT), United Kingdom (Clinical Audit Registration and Management 
System: CARMS-15001) with data collection approved by NHS 
National Research Ethics Committee (14/LO/1208), IIH:LIFE study. 
The study was conducted from October 2018 to August 2020 with 
ongoing patient follow-up in routine care and analysis performed in 
August 2020. This was a prospective evaluation and we report the 
primary analysis of the data.
Study patients
Patients were recruited and data collected prospectively from a ter-
tiary Neuroscience public sector, Headache Centre at UHB NHS FT, 
UK. Adult patients with IIH in ocular remission and chronic head-
aches presenting to the Headache Centre were screened for suit-
ability of erenumab therapy (Aimovig®, Novartis). Patients were 
treated with erenumab on a free of charge scheme through the NHS 
funded by Novartis. The number of patients recruited was deter-
mined by the recruitment of every consecutive patient who met the 
eligibility criteria from October 2018 to August 2019. All patients 
received free treatment throughout their care.
Eligible patients had chronic moderate/severe headaches (≥15 per 
month).26,27 All patients had IIH in ocular remission, defined as previ-
ous diagnosis of IIH with resolution of papilledema.1 Study patients 
were adults (≥18 years) for whom ≥3 prior prophylactic treatments 
had failed. Treatment failure was defined as any of the following: in-
adequate efficacy with appropriate dosing and treatment duration; 
intolerable adverse effects; contraindications preventing use; safety 
concerns.28 Drug treatment attempts were defined as: inadequate 
efficacy with appropriate dosing and treatment duration or intoler-
able adverse effects. Patients with a history of headache attributed 
to intracranial hypotension (apart from short-lasting post-lumbar 
puncture headache) were excluded. Patients were not on topiramate 
or acetazolamide at erenumab initiation.
Study design
An open-label, prospective cohort study was conducted to investi-
gate use of erenumab in chronic headache in patients with IIH in oc-
ular remission. Patients had access to a full range of advice from the 
Headache Centre as part of routine care. Patients with all degrees 
of medication overuse headache (MOH), including opiate overuse 
were included.28 MOH was defined according to the International 
Classification of Headache Disorders 3b: “headache occurring on 
≥15 days/month in a patient with a pre-existing primary headache 
and developing as a consequence of regular overuse of acute or 
Conclusions: This study provides evidence for the effectiveness of erenumab to treat 
headaches in IIH patients with resolution of papilledema. It provides mechanistic in-
sights suggesting that calcitonin gene-related peptide is likely a modulator driving 
headache and a useful therapeutic target.
K E Y W O R D S
calcitonin gene-related peptide monoclonal antibody, headache, idiopathic intracranial 
hypertension, papilledema, raised intracranial pressure
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symptomatic headache medication (≥10 or ≥15 days/month, de-
pending on the medication) for more than 3 months.”26
Following the baseline monthly headache diary, patients meet-
ing the eligibility criteria were fully informed of the potential ben-
efits and side effects and signed a written consent to proceed with 
subcutaneous erenumab (Aimovig®, Novartis). A full neurological 
and ophthalmological review was performed by a neurologist and 
a neuro-ophthalmologist including optical coherence tomography 
(OCT) imaging (Heidelberg Engineering SPECTRALIS, Heidelberg, 
Germany) and dilated slit-lamp examination of the fundus to confirm 
resolution of papilledema.
Patients were taught erenumab self-administration and com-
menced at 70 mg 4-weekly injections. Response was assessed at 
3-monthly follow-up consultations by phone or clinic visit over a 
12-month period. Monthly headache diaries, IIH symptoms, and 
Headache Impact Test (HIT-6)29 were reviewed every 3 months; 
Medical Outcomes Study Short Form (SF-36) Health Survey (RAND 
36-Item Health Survey 1.0),30,31 hospital anxiety and depression scale 
(HADS),32 and four-item self-fulfilled questionnaire to predict nocebo 
effect (Q-No) questionnaire33 were reviewed at baseline, 6 months, 
and 12 months. Monthly moderate/severe headache days (MmsHD), 
monthly total headache days (MHD), headache severity (0–10 nu-
merical rating scale [NRS]), crystal clear days (day without any head 
pain), days using analgesia, and symptoms associated with IIH (but not 
pathognomonic as they can also be reported in other headache condi-
tions34) were derived from the monthly headache diaries.
Dosing was determined from the change in MmsHD, MHD, 
headache severity, or HIT-6 score at the 3-monthly follow-up con-
sultations. Where the response was ≤50% but ≥30% the dose was 
increased to 140 mg. Those with ≥50% response continued on ere-
numab at the 70 mg dose. Those with <30% response were discon-
tinued from treatment.
Study outcomes
Primary end point was the mean change in MmsHD between the 
30-day pretreatment period compared to 12 months. Data were also 
reported at 3, 6, and 9 months. A moderate/severe headache day 
was defined as a day with moderate or severe pain that last at least 4 
hours or those requiring the use of abortive therapy.28
Secondary end points included the MHD. MHD were all 
headache days, defined as those with an onset, continuation or 
recurrence any severity or phenotype of headache, lasting at 
least 30 minutes.8 Other secondary end points were: crystal clear 
days (days with no headache), change in headache severity (head-
ache severity was evaluated using a NRS; 0 [no pain] to 10 [most 
severe pain]), monthly analgesic days, responder rates (percent-
age of patients achieving at least 30%, 50%, and 75% reduction 
of MmsHD and MHD), and symptoms associated with IIH (dou-
ble vision, blurred vision, pulsatile tinnitus, and visual obscura-
tions).1 Patient reported outcome measures included absenteeism 
(days off duty due to disability), presenteeism (days with loss of 
productive capacity during duties),35 HIT-6 at all time-points, 
and HADS, SF-36 (physical component summary score [PCS] and 
mental component summary score [MCS]), and Q-No at baseline, 
6, and 12 months. Outcomes were in line with the guidelines of 
the International Headache Society (IHS) for studies of preventive 
treatment of chronic migraine in adults.28 Patient reported out-
comes are not specific to IIH (as these have not been yet devel-
oped) but have been used in previous IIH trials.36–38
Statistical analysis
Statistical analyses were undertaken on SPSS (Armonk, NY: IBM Corp. 
Version 25.0 [2017]). Data were predominantly normally distributed 
and consequently represented as mean and standard deviation (SD) 
unless otherwise specified. End points were compared between the 
30-day pretreatment period and 12 months, with secondary analyses 
at 3, 6, and 9 months, using a two-tailed paired t-test where data were 
normally distributed or Wilcoxon signed rank test where data were not 
normally distributed. A prespecified subgroup analyses was performed 
on those with and without MOH at baseline.28 Additionally, we ana-
lyzed those with and without a preexisting diagnosis of migraine prior 
to being diagnosed with IIH. We have performed a further post hoc 
sensitivity analysis for key end points to account for the missing data 
for patients that erenumab was stopped through imputation by carry-
ing forward the last observed values at the time-point that erenumab 
was stopped for the subsequent time-points. Statistical significance 
was considered at p < 0.05 level (two-tailed) unless otherwise stated 
and p-values were unadjusted. As this was a prospective service evalu-
ation study, no power calculations were performed. All patients avail-
able for follow-up were included in the analysis. Missing data were 
noted in the results and all the authors had access to the study data.
RESULTS
Demographics
Fifty-five patients with IIH in ocular remission and chronic head-
aches were included in the study (Figure 1). The headache pheno-
type was chronic migraine-like in 55/55 (100%) of the patients. All 
patients were female, with a mean (SD) age of 35.3 (9) years. The 
duration of chronic headaches since the papilledema had resolved 
was 1.7 (2.5) years. MOH occurred in 27/55 (48%) and family history 
of migraine in 24/55 (44%) patients (Table 1).
The majority of patients 48/55 (87%) required a dose increase 
at the 3 months, while 6 (11%) continued on 70 mg. At 6 months, 
3 (6%) continued on 70 mg and in 48 (89%) the dose was 140 mg 
(Figure 1). At 9 months, 2 (4%) continued on 70 mg and in 46 (90%) 
the dose was 140 mg. At 12 months, 2 (4%) continued on 70 mg and 
in 45 (94%) the dose was 140 mg. By 12 months, erenumab had been 
discontinued in eight (15%) patients (six ineffective, one pregnant, 
and one noncompliant).
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Baseline headache, medications, quality of life,  
and IIH characteristics
The population recruited had severe chronic resistant headache. 
At baseline the mean duration of headaches was 10.4 (8.4) years. 
Among the subgroup with migraine prior to IIH, the duration of head-
aches was 15.6 (8.2) years, and among those with no migraine prior 
to IIH diagnosis, the total duration of headaches was 5.1 (4.3) years.
The baseline frequency of moderate/severe headaches and total 
headache days was high (MmsHD 16.1 (4.7), MHD 29.0 (2.3)), and 
importantly had been high and refractory to treatment for at least 
a year (12-month prior MmsHD 14.5 (5.2) and MHD 28.3 (3.8)). 
Headache severity was 6 (1.3) NRS with severe impact on activities 
(HIT-6 score 67.2 (4.4), Table 1). The mean (SD) number of failed pre-
ventative treatments was 3.7 (0.9).
Symptoms reported by patients associated with IIH were noted 
at baseline: 21/55 (38%) reported variable double vision (without 
evidence of a cranial nerve palsy on extraocular movement examina-
tion), 42/55 (76%) blurred vision, 49/55 (89%) pulsatile tinnitus, and 
19/55 (35%) transient visual obscurations. Clinical examination con-
firmed no cranial nerve palsies and slit-lamp examination confirmed 
no ongoing papilledema. Mean (SD) peripapillary retinal nerve fiber 
layer thickness at baseline was 98 (17.8) µm for right eyes and 100 
(20.9) µm for left eyes, as quantified by OCT. During the 12-month 
follow-up, seven patients experienced weight gain and recurrence of 
papilledema, details of these cases are reported separately39 but they 
remain in the overall analysis to reduce bias from loss to follow-up.
Efficacy
There was a substantial improvement in the primary end point of 
MmsHD at 12 months (reduction of mean (SD) [95% CI (confidence 
interval)] −10.8 (4.0) [−9.5, −11.9] days, p < 0.001) (Figure 2A, Table 2), 
F I G U R E  1  Flowchart of patient recruitment and follow-up
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TA B L E  1  Baseline patient characteristics
Characteristic Years, mean (SD)
Total cohort, no. (all female) 55
Age 35.3 (9)
Duration of chronic headache 10.4 (8.4)
Duration of chronic headaches by subgroup
Migraine prior to IIH 15.6 (8.2), (52%, n = 28)
No migraine prior to IIH 5.1 (4.3), (48%, n = 27)
Duration of headache following resolution of papilledema (ocular remission) 1.7 (2.5)
History of previous preventative treatment failure Mean (SD)
Drug treatment trial attemptsa  2.2 (1.5)
Failed drugsb   3.7 (0.9)
No. (%)
Trial attempt of ≥1 49 (89%)
Trial attempt of ≥2 33 (60%)
Trial attempt of ≥3 20 (36%)
Trial attempt of ≥4 13 (24%)
Failure of ≥3 55 (100%)
Clinical characteristic No. (%)
Migraine prior to IIH 28 (52%)
No migraine prior to IIH 27 (48%)
Childhood migraine 9 (16%)
Teenage migraine 26 (47%)
Family history of migraine 24 (44%)
Medication overuse headache (MOH) 27 (48%)
Opioid use 16 (29%)
Mental health comorbidities (anxiety/depression) 22 (40%)
Significant alcohol history 0
Mean (SD), unless otherwise specified
Monthly moderate/severe headache days (MmsHD)
Baseline 16.1 (4.7)
12 months prior 14.5 (5.2)
Monthly total headache days (MHD)
Baseline [median (IQR)] 29.0 (2.3) [30 (30–30)]
12 months prior [median (IQR)] 28.3 (3.8) [30 (30–30)]
Headache severity (NRS) baseline
Baseline 6 (1.3)
12 months prior 6.2 (1.7)
Monthly analgesic days 9 (7.3)
Monthly triptan days 2.9 (4.1)
Monthly crystal clear days [median (IQR)] 0.9 (2.1) [0 (0–0)]
Monthly absenteeism days [median (IQR)] 11.8 (11.5) [7.5 (2–20)]
Monthly presenteeism days [median (IQR)] 21.1 (8) [20 (15–30)]
HADS anxiety score 10.1 (4.6)
HADS depression score 8.9 (4.3)
HIT-6 score 67.2 (4.4)
Q-No score 15.3 (6.5)
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F I G U R E  2  Effect of erenumab on key end points. (A) Change in mean number of monthly moderate/severe headache days from baseline 
to 3, 6, 9, and 12 months. Error bars represent 95% Confidence intervals (CIs). (B) Percentage change in mean number of monthly moderate/
severe headache days from baseline to 3, 6, 9, and 12 months. Error bars represent 95% CIs. (C) Percentage of patients with at least a 30%, 
50%, and 75% reduction in their monthly moderate/severe headache days from baseline to 3, 6, 9, and 12 months (responder rates). Number 
above bars represents the percentage of patients. (D) Change in mean number of monthly total headache days from baseline to 3, 6, 9, and 
12 months. Error bars represent 95% CIs. (E) Percentage change in mean number of monthly total headache days from baseline to 3, 6, 
9, and 12 months. Error bars represent 95% CIs. (F) Percentage of patients with at least a 30%, 50%, and 75% reduction in their monthly 
total headache days from baseline to 3, 6, 9, and 12 months (headache responder rates). Number above bars represents the percentage of 
patients. (G) Mean number of absenteeism and presenteeism days as reported by patients at baseline and at 3, 6, 9, and 12 months. Error 
bars represent 95% CIs. (H) Mean number of analgesic days at baseline and at 3, 6, 9, and 12 months. Error bars represent 95% CIs. (I) Mean 
headache impact test-6 (HIT-6) score at baseline and at 3, 6, 9, and 12 months. Error bars represent 95% CIs. MHD, monthly total headache 
days; MICD, minimally important clinical difference; MmsHD, monthly moderate/severe headache days. ***p < 0.001 compared to baseline, 
**p < 0.01 compared to baseline, *p < 0.05 compared to baseline
TA B L E  1 ( Continued)
Mean (SD), unless otherwise specified
SF-36—Physical summary scorec  36.3 (18)
SF-36—Mental summary scorec  38.2 (15.6)
aDrug treatment attempts: ineffective/intolerant. 
bFailed drugs: ineffective/intolerant/contraindicated/safety concerns. 
cn = 53. 
Abbreviations: HADS, hospital anxiety and depression scale; HIT-6, headache impact test-6; IIH, idiopathic intracranial hypertension; IQR, 
Interquartile range; MHD, monthly total headache days; MmsHD, monthly moderate/severe headache days; NRS, numeric rating scale (0 = no pain to 
10 = worst imaginable pain); Q-No, four-item self-fulfilled questionnaire to predict nocebo effect; SF-36, Short Form-36 Health Survey.
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with significant improvement from 3 months which continued over 
the study period to 12 months.
The overall MHD also significantly improved from 3 months 
and at all time-points to 12 months (MHD reduced by −13.0 (9.5) 
[−10.2, −15.7] at 12 months, p < 0.001) (Figure 2D, Table 2). The 
responder rates for moderate/severe headache and totalhead-
ache days are shown in Figure 2C,F and notably 85% (41/48) of 
patients achieved a 50% reduction of moderate/severe headache 
days and 54% (26/55) achieved a 50% reduction in totalheadache 
days (Table 2). By 12 months, 52% (25/48) had a ≥75% moder-
ate/severe headache responder rate. The number of crystal clear 
days increased from 0.9 (2.1) to 8.6 (8.3) at 3 months, 11.2 (9.1) 
at 6 months, 11.3 (9) at 9 months, and 13.9 (9.8) at 12 months, 
p < 0.001 (Table 2). Headache severity reduced by −1.3 (1.7) [−0.9, 
−1.9] points at 12 months, p < 0.001.
Accompanying the improvements in headaches we noted a con-
sistent significant reduction in frequency of analgesic use from the 
3-month time-point continuing until 12 months (3 months −3.4 (7.8) 
[−1.3, −5.5] days, 6 months −4.0 (8.1) [−1.8, −6.2] days, 9 months 
−4.4 (7.8) [−2.2, −6.6] days, and 12 months −4.3 (9.2) [−1.6, −6.9], 
p = 0.002 (Table 2, Figure 2H). Presenteeism and absenteeism sig-
nificantly improved (Table 2, Figure 2G).
TA B L E  2  Primary and key secondary end point results
3 months (n = 55) 6 months (n = 54) 9 months (n = 51) 12 months (n = 48)
Primary end point (mean (SD)[95% CI])
MmsHD change −8.6 (3.9) [−7.6, −9.7] −10.1 (4.7) [−8.8, −11.4] −9.5 (4.7) [−8.3, −11.1] −10.8 (4.0) [−9.5, −11.9]
p-valuea  <0.001 <0.001 <0.001 <0.001
Secondary end points (mean (SD) [95% CI], unless otherwise stated)
MHD change −8 (8.1) [−5.5, −9.6] −10.5 (8.7) [−7.9, −12.8] −9.8 (8.5) [−7.5, −12.3] −13.0 (9.5) [−10.2, −15.7]
p-valueb  <0.001 <0.001 <0.001 <0.001
Crystal clear days change 7.7 (7.7) [5.6, 9.8] 10.3 (9) [7.8, 12.7] 10.3 (8.8) [7.8, 12.8] 13.1 (9.5) [9.6, 15.3]
p-valueb  <0.001 <0.001 <0.001 <0.001
Headache severity change (NRS) −1.2 (1.5) [−0.8, −1.61] −1.3 (1.6) [−0.8, −1.7] −1 (1.6) [−0.5, −1.4] −1.3 (1.7) [−0.9, −1.9]
p-valuea  <0.001 <0.001 <0.001 <0.001
Monthly analgesic days change −3.4 (7.8) [−1.3, −5.5] −4.0 (8.1) [−1.8, −6.2] −4.4 (7.8) [−2.2, −6.6] −4.3 (9.2) [−1.6, −6.9]
p-valuea  0.002 0.001 <0.001 0.002
Monthly triptan days change −0.3 (4.3) [−0.9, 1.5] −0.8 (3.7) [−0.3, 1.8] −0.9 (4) [−0.9, 1.8] −1 (4.6) [−0.4, 2.4]
p-valuea  0.615 0.183 0.498 0.153
Responder rates moderate/severe headaches/all headache (%)
≥30% 89%/44% 91%/57% 88%/57% 98%/65%
≥50% 62%/25% 69%/50% 76%/29% 85%/54%
≥75% 18%/5% 39%/19% 43%/10% 52%/25%
Main patient reported outcomes, mean (SD)
Monthly absenteeism days change −4.7 (8.3) [−2.1, −6.5] −7.0 (11.4) [−3.5, −9.6] −6.7 (11.9) [−3.0, −9.6] −7.1 (11.5) [−2.9, −9.5]
p-valueb  <0.001 <0.001 <0.001 <0.001
Monthly presenteeism days 
change
−10.8 (8.3) [−8.5, −13.1] −12.3 (11.1) [−9.4, −15.2] −11.2 (12.2) [−7.8, −14.6] −12.7 (10.1) [−9.5, −15.5]
p-valueb  <0.001 <0.001 <0.001 <0.001
HIT-6 score change −6.1 (10) [−3.3, −9.0] −7.7 (8.3) [−5.3, −10.1] −6.9 (8.8) [−4.6, −9.6] −7.6 (8.7) [−4.7, −10.0]
p-valuea  <0.001 <0.001 <0.001 <0.001
IIH symptoms, No. (%) Baseline (n = 55) 3 months (n = 55) 6 months (n = 54) 9 months (n = 51) 12 months (n = 48)
Double vision 21 (38%) 22 (40%) 5 (9%) 7 (14%) 12 (25%)
Blurred vision 42 (76%) 38 (69%) 31 (57%) 35 (69%) 31 (65%)
Pulsatile tinnitus 49 (89%) 47 (85%) 35 (65%) 39 (77%) 35 (73%)
Visual obscurations 19 (35%) 22 (40%) 6 (11%) 7 (14%) 4 (8%)
aPaired t-test compared to baseline. 
bWilcoxon signed ranks test compared to baseline. 
Abbreviations: CI, confidence interval; HIT-6, headache impact test-6; IIH, idiopathic intracranial hypertension; MHD, monthly total headache days; 
MmsHD, monthly moderate/severe headache days; NRS, numeric rating scale (0 = no pain to 10 = worst imaginable pain).
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Patient reported outcome measures
There was a substantial reduction in the headache disability as re-
ported by the HIT-6 score (from 67.4 (4.4) at baseline to 60.9 (9.2) at 
3 months, 59.1 (7.4) at 6 months, 60 (8.4) at 9 months, and 59.7 (8.6) 
at 12 months p < 0.001 (Table 2, Figure 2I). There were no nota-
ble reductions in the HADS-A, HADS-D, and Q-NO score (Table 3). 
However, quality of life, evaluated at 6 months and 12 months 
using the SF-36 score showed significant improvement in the PCS 
(36.3 (18) at baseline to 44.9 (22.2) at 6 months and 49.0 (24.8) at 
12 months) and in the MCS (38.2 (15.6) at baseline to 48.0 (18.1) at 
6 months and 45.2 (21.5) at 12 months) (Table 3).
Subanalyses
A subanalysis was performed in those with migraine prior to their 
IIH diagnosis (28/55 (52%), mean (SD) baseline MmsHD 15.3 
(4.3)), and those with no prior migraine before their IIH diagno-
sis (27/55 (48%), mean (SD) baseline MmsHD 16.9 (4.9)). Prior mi-
graine diagnosis was established from review of medical records 
and patient reporting the diagnosis. Results were also equivalent 
between these groups with reduction in MmsHD at 3 months −7.6 
(3.1) [−6.6, −9.0] and −9.6 (4.5) [−7.8, −11.4], at 6 months −9.5 (4.1) 
[−8.0, −11.1] and −10.7 (5.4) [−8.5, −12.8], at 9 months −7.8 (4.2) 
[−6.2, −9.8] and −11.5 (4.4) [−9.7, −13.5], and at 12 months −9.9 (3.6) 
[−8.2, −11.2], p < 0.001 and −11.9 (4.2) [−10.0, −13.8], p < 0.001 
(Figure 3A,B, Table 4).
A further subanalysis was performed for outcomes in those with 
MOH (27/55 (48%) mean (SD) baseline MmsHD 16.4 (4.7)) and those 
without MOH (28/55 (52%) mean (SD) baseline MmsHD 15.7 (4.7)) 
at baseline. Results were equivalent between groups with reduction 
in MmsHD at 3 months −8.5 (3.7) [−7.2, −10.1] and −8.7 (4.3) [−7.0, 
−10.3], at 6 months −10.4 (4.8) [−8.6, −12.4] and −9.7 (4.7) [−7.8, 
−11.5], at 9 months −9.4 (3.8) [−7.9, −11.3] and −9.6 (5.4) [−7.6, −12.0], 
and at 12 months −11.0 (3.8) [−9.1, −12.6], p < 0.001 and −10.6 (4.2) 
[−8.9, −12.4], p < 0.001 (Figure 3C,D).
Additionally, 14 patients did not have a migraine diagnosis prior 
to IIH and no MOH and improvements were equivalent with the 
other groups (Table 4). The above subanalyses were performed for 
MHD with significant improvements at all time-points in all sub-
groups (Table 4).
A sensitivity analysis was conducted to account for missing data 
(n = 7 at 12 months) (last observation carried forward), the change 
in MmsHD was −10.1 (4.8) [−8.8, −11.4] and MHD −11.4 (9.9) [−8.7, 
−14.1] at 12 months (p < 0.001) (Table 5).
Safety and tolerability
Side effects were reported in 21/55 (38%) patients. These included 
constipation 9 (16%), generalized muscle cramps or spasms 6 (11%), 
generalized itching 3 (5%), generalized skin rash 3 (5%), injection site 
pain 3 (5%), hair thinning 2 (4%), nasopharyngitis 1 (2%), and acne 
1 (2%). These side effects were not deemed serious and no patient 
discontinued treatment due to side effects. At 1 year 10/48 (21%) 
patients reported side effects. Seven patients from our cohort 
suffered recurrence of raised ICP, as evidenced by a return of the 
papilledema, however, the headaches did not recur while treated 
with erenumab. We have reported these patients individually as a 
case series.39
DISCUSSION
This prospective open-label study demonstrates the efficacy of 
erenumab to improve headaches in patients with IIH in whom the 
papilledema has resolved (ocular remission). The response was 
marked given that the population recruited had chronic, long dura-
tion, resistant headaches, and approximately half had MOH.
TA B L E  3  Patient reported outcomesa
Mean (SD) [95% CI] Baseline 6 months Change p-value 12 months Change p-value
HADS N = 55 N = 35 N = 31
Anxiety score 10.1 (4.6) 8.5 (4.8) −1.3 (4.4) [−0.2, 2.9] 0.083 10.1 (4.9) −0.3 (3.3) [−0.9, 1.5] 0.593
Depression score 8.9 (4.3) 7.8 (4.7) −1.1 (4.6) [−0.5, 2.7] 0.163 8.9 (5.5) 0.0 (4.9) [−1.8, 1.8] 1
Q-No N = 55 N = 39 N = 28
Score 15.3 (6.5) 14.1 (5.0) −1.5 (8.1) [−1.3, 3.9] 0.304 15.0 (4.3) −1.8 (8.1) [−1.4, 4.9] 0.255
SF-36 N = 53 N = 24 N = 30
Physical component 
summary (PCS)
36.3 (18.0) 44.9 (22.2) 11.7 (21.6) [2.6, 20.8] 0.014 49.0 (24.8) 10.6 (25.4) [1.2, 20.1] 0.029
Mental component 
summary (MCS)
38.2 (15.6) 48.0 (18.1) 12.6 (17.0) [5.4, 19.8] 0.001 45.2 (21.5) 7.7 (20.0) [0.3, 15.2] 0.043
Note: Data presented as Mean (SD). p-values represent 6 and 12 months change compared to baseline (Paired t-test).
aOnly fully completed returned questionnaires were included in the analysis. 
Abbreviations: HADS, hospital anxiety and depression scale; Q-No, four-item self-fulfilled questionnaire to predict nocebo effect; SF-36, Short Form-
36 Health Survey.
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In these IIH patients with persistent headaches following reso-
lution of papilledema, the moderate/severe headache days reflected 
migraine-like headache days. Erenumab reduced the frequency of 
moderate/severe headache days by 71% and total headache days 
by 45% from baseline to 12 months. Further, erenumab significantly 
increased crystal clear days, reduced analgesic days, reduced sever-
ity and reduced absenteeism and presenteeism. Headache disabil-
ity and quality of life (HIT-6 score and SF-36 PCS and SF-36 MCS) 
also significantly improved. The majority of patients required an in-
creased dose of erenumab to 140 mg monthly (87% at 3 months, 
89% at 6 months, 90% at 9 months, and 94% by 12 months). The 
treatment was well tolerated with no patient withdrawals related to 
adverse effects and only six discontinuing due to lack of effect (by 
12 months). Similar efficacy was seen in those without a diagnosis of 
previous migraine (48% of the cohort).
There are few pharmacotherapies in IIH although novel ther-
apeutic approaches are being developed to target reduction in 
ICP.36,40–42 However, despite overwhelming evidence of the head-
ache burden in IIH,4,8 treatments specifically aimed at managing 
headache in IIH have not been previously evaluated. In routine care, 
existing migraine preventative drugs are used off label, without ev-
idence of efficacy in this population. Furthermore, they are often 
not tolerated or contraindicated in IIH patients due to the risk of 
exacerbating obesity (a key driver for raised ICP) and mood disor-
ders. Hence, this study marks an important step forward to establish 
targeted headache treatments for IIH patients with chronic head-
aches in whom papilledema has resolved.
Our results, while open-label, are in line with randomized 
controlled trial data evaluating erenumab in chronic migraine pa-
tients.22,43 IIH patients with MOH were included, reflecting real-life 
populations44 and in line with IHS guidelines for chronic migraine 
trials.28 MOH was common among this IIH cohort (48%) as has been 
noted in previous IIH populations.8 This study demonstrates equiv-
alent efficacy of erenumab to reduce headache in those with and 
without MOH at baseline. Additionally analgesic use reduced signifi-
cantly over the study period, an outcome also noted in the erenumab 
chronic migraine trial.22
The IIH patients had severely disabling headaches at baseline, 
as demonstrated by the HIT-6 score.45 The reductions in the HIT-6 
score by −7.6 at 12 months is both clinically and statistically sig-
nificant (minimal important clinical difference in HIT-6 is 5).45 The 
improvements in symptoms associated with IIH were only mod-
est, with a fluctuating course through the duration of the study. 
These symptoms are not pathognomonic for IIH and often asso-
ciated with other headache disorders and should be interpreted 
with caution.34
F I G U R E  3  Effect of erenumab on headache in those with and without previous migraine and medication overuse headache. Change in 
mean number of monthly moderate/severe headache days from baseline to 3, 6, 9, and 12 months. Error bars represent 95% confidence 
intervals (CIs). (A) Patients with migraine diagnosis prior to IIH diagnosis. (B) Patients without migraine diagnosis prior to IIH diagnosis. (C) 
Patients with MOH at baseline. (D) Patients without MOH at baseline. IIH, idiopathic intracranial hypertension; MOH, medication overuse 
headache. ***p < 0.001 compared to baseline
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Quality of life evaluated by the SF-36 domains (physical compo-
nent and MCSs) improved significantly at 12 months (change in PCS 
12.2; MCS 8.7, respectively). There was minimal change in the Hospital 
Anxiety and depression score (HADS) in our study, however, 40% of 
our cohort had a concurrent mental health disorder being actively 
managed which may have impacted the results. The Q-No score was 
elevated at baseline (>15) reflecting a heightened nocebo response 
potentially driven by problematic side effects encountered during 
TA B L E  4  Subanalysis of patients with/without migraine prior to IIH diagnosis and with/without MOH
Mean (SD) [95% CI], unless 
otherwise specified Baseline 3 months 6 months 9 months 12 months
Patients with migraine 
diagnosis prior to IIH
N = 28 N = 28 N = 28 N = 27 N = 25
MmsHD 15.3 (4.3) 7.5 (4.1) 5.7 (4.4) 7 (6.1) 5.0 (4.1)
MmsHD change −7.6 (3.1) [−6.6, −9.0] −9.5 (4.1) [−8.0, −11.1] −7.8 (4.2) [−6.2, −9.8] −9.9 (3.6) [−8.2, −11.2]
p-value <0.001 <0.001 <0.001 <0.001
MHD 29.6 (1.1) 22.5 (8.0) 19.6 (8.7) 20.6 (9.2) 16.6 (9.7)
MHD change −7.1 (7.6) [−4.1, −10.0] −10.0 (8.6) [−6.7, −13.3] −8.5 (9) [−5.5, −12.6] −13.0 (9.7) [−8.4, −16.3]
p-value <0.001 <0.001 0.001 <0.001
Patients without migraine 
diagnosis prior to IIH
N = 27 N = 27 N = 26 N = 24 N = 23
MmsHD 16.9 (4.9) 7.3 (3.8) 6.3 (4.6) 5.6 (5.3) 4.4 (3.8)
MmsHD change −9.6 (4.5) [−7.8, −11.4] −10.7 (5.4) [−8.5, −12.8] −11.5 (4.4) [−9.7, −13.5] −11.9 (4.2) [−10.0, −13.8]
p-value <0.001 <0.001 <0.001 <0.001
MHD 28.3 (−2.9) 20.3 (8.5) 17.5 (9.6) 17.9 (9.3) 15.3 (10.0)
MHD change −8.9 (8.5) [−5.0, −11.0] −11.1 (8.9) [−7.0, −14.5] −10.7 (9.3) [−7.4, −14.2] −13.1 (9.4) [−9.6, −17.8]
p-value <0.001 0.001 0.001 <0.001
Patients with MOH N = 27 N = 27 N = 25 N = 25 N = 24
MmsHD 16.4 (4.7) 7.8 (3.7) 6.0 (4.3) 6.2 (5) 4.5 (3.4)
MmsHD change −8.5 (3.7) [−7.2, −10.1] −10.4 (4.8) [−8.6, −12.4] −9.4 (3.8) [−7.9, −11.3] −11.0 (3.8) [−9.1, −12.6]
p-value <0.001 <0.001 <0.001 <0.001
MHD 28.3 (2.9) 20.4 (8.5) 18.8 (9.2) 19.6 (9.7) 16.4 (10.5)
MHD change −7.6 (7.5) [−4.3, −10.2] −9.9 (8.7) [−5.9, −13.1] −8.7 (9.3) [−4.7, −12.3] −12.0 (10.0) [−7.6, −16.0]
p-value <0.001 <0.001 0.002 <0.001
Patients without MOH N = 28 N = 28 N = 27 N = 26 N = 24
MmsHD 15.7 (4.7) 7.0 (4.2) 6 (4.7) 5.9 (5.6) 5.0 (4.4)
MmsHD change −8.7 (4.3) [−7.0, −10.3] −9.7 (4.7) [−7.8, −11.5] −9.6 (5.4) [−7.6, −12.0] −10.6 (4.2) [−8.9, −12.4]
p-value <0.001 <0.001 <0.001 <0.001
MHD 29.6 (1.1) 22.4 (8.1) 18.4 (9.1) 18.5 (8) 15.5 (9.3)
MHD change −8.3 (8.7) [−4.3, −10.2] −11.2 (8.8) [−7.7, −14.7] −11.2 (7.8) [−8.0, −14.3] −14.1 (9.0) [−10.3, −17.9]
p-value <0.001 <0.001 0.002 <0.001
Patients without prior 
migraine and without 
MOH
N = 14 N = 14 N = 13 N = 12 N = 12
MmsHD 17.1 (5.2) 6.8 (4.7) 6.2 (5.1) 4.8 (4.2) 5.3 (4.9)
MmsHD change −10.3 (5.0) [−7.4, −13.2] −10.9 (5.9) [−7.3, −14.5] −12.1 (4.8) [−9.5, −15.5] −12.1 (4.6) [−9.2, −15.0]
p-value <0.001 <0.001 <0.001 <0.001
MHD 29.6 (0.7) 21.2 (8.8) 16.2 (9.2) 16.9 (6.9) 16.8 (10.6)
MHD change −10.6 (10.0) [−3.4, −13.4] −13.5 (9.0) [−8.0, −19.0] −12.2 (6.8) [−8.5, −17.2] −12.9 (10.5) [−6.3, −19.6]
p-value 0.008 0.003 0.005 0.008
Note: Data presented as Mean (SD) [95% Confidence Interval], unless otherwise specified. Statistical tests represent paired t test for MmsHD and 
Wilcoxon signed ranks test for MHD for the 3, 6, 9, and 12 months end points compared to baseline.
Abbreviations: CI, Confidence interval; IIH, idiopathic intracranial hypertension; MHD, monthly total headache days; MmsHD, monthly moderate/
severe headache days; MOH, medication overuse headache.
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previous medication trials.33 The score did not change greatly during 
the study (15.3 (6.5) at baseline, decreasing to 15 (4.3) at 12 months).
There was a strong family history of migraine (24/55, 44%) among 
the IIH patients with resistant chronic headaches recruited into this 
study. We speculate that, as is noted among chronic posttraumatic 
headache patients, a family history of migraine may represent a poor 
prognostic marker for progression of chronic IIH headaches.46–48
This study suggests that the CGRP pathway is likely a key modu-
lator of headache in patients with IIH and that targeting CGRP may 
be a useful therapeutic strategy to manage headache. We hypoth-
esize, as is suggested in other secondary headache disorders, that 
raised ICP drives trigeminovascular activation and CGRP release 
which continues even after the original insult of the raised ICP has 
subsided.25,49,50 In support of the role of CGRP in driving headache 
mechanisms in the setting of raised ICP we evaluated the treatment 
response in IIH patients with and without a history of migraine head-
aches prior to the diagnosis of IIH. We noted a significant treatment 
response even in those with no prior migraine diagnosis, suggesting 
a role of CGRP in headache precipitated by raised ICP.
The open-label, prospective, study design is limited as there is 
no comparator group, thus, no ability to assess any potential pla-
cebo response which is known to be high with injectable headache 
therapies.51 The placebo response in a randomized controlled trial 
of erenumab was 23% at 12 weeks.22 However, the relatively long 
(12 months) duration of follow-up with sustained therapeutic re-
sponse points away from a predominant placebo response as this 
would typically wain with time. Open-labeled studies do need to 
be interpreted with caution as response may reflect regression to 
the mean, spontaneous fluctuation, or disease progressing into re-
mission. Furthermore, weight loss can improve headaches in IIH.6 
During this study, patients were not on a formal weight management 
program; however, we anticipate that all would have been aware of 
the importance of weight management in maintaining their IIH in oc-
ular remission. As the majority of follow-up visits were by phone, 
weight was not formally assessed, but in those describing weight gain 
we formally assessed for recurrence of papilledema.39 We cannot ex-
clude the possibility that weight loss could have occurred in these 
patients during follow-up. However, the above are unlikely to be the 
principal factors explaining our results as the cohort at baseline were 
experiencing a consistently high headache load, with similar MmsHD 
and MHD 12 months prior to baseline (MmsHD 12 months pre- 
enrolment 14.5 (5.2) and 16.1 (4.7) at baseline and MHD 12 months 
pre-enrolment 28.3 (3.8) and 29 (2.3) at baseline). Thus, the baseline 
headache frequency at study entry was consistently high and un-
changing over a prolonged period (when similar approaches and fluc-
tuations would have occurred) until the erenumab was commenced. 
Furthermore, a limitation of this study was that non-responders were 
not followed up and this could have inflated the outcomes. However 
very low numbers of patients were lost to follow-up by 12 months 
(five ineffective, one pregnant, and one noncompliant). The sensi-
tivity analysis revealed similar significant improvements for key end 
points even when missing data were imputed (Table 5). Missing data 
for the primary end point were n = 7 but was higher for the patient 
reported outcome questionnaires as the majority of follow-up visits 
were by phone, enabling the majority of the data to be collected at 
the time of the visit, however, we required patients to post back the 
questionnaires which led to greater missing data.
CONCLUSION
This prospective open-label study of erenumab in IIH patients with 
persistent headaches in whom their papilledema has resolved, dem-
onstrates significant efficacy to reduce headaches. The moderate/
severe headaches days reflected migraine-like headaches in this IIH 
cohort. Erenumab had similar efficacy among the 48% who had no 
prior history of migraine. Targeting CGRP is likely to be a useful ther-
apeutic strategy and worthy of evaluation in a future randomized 
controlled trial. The mechanisms driving headache in patients with 
IIH have not been previously evaluated or understood. These data 
provide important mechanistic insights suggesting that CGRP is 
likely a key modulator driving headache in patients with IIH.
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TA B L E  5  Subanalysis for key end points with missing data imputed
3 months (n = 55) 6 months (n = 55) 9 months (n = 55) 12 months (n = 55)
Primary end point (mean (SD) [95% CI])
MmsHD change −8.6 (3.9) [−7.6, −9.7] −9.9 (4.8) [−8.6, −11.2] −9.5 (5.1) [−8.1, −10.9] −10.1 (4.8) [−8.8, −11.4]
p-value <0.001 <0.001 <0.001 <0.001
Secondary end point (mean (SD) [95% CI])
MHD change −8 (8.1) [−5.5, −9.6] −10.2 (8.9) [−7.8, −12.6] −9.3 (8.5) [−7.0, −11.6] −11.4 (9.9) [−8.7, −14.1]
p-value <0.001 <0.001 <0.001 <0.001
Note: Imputation for missing data performed by carrying forward the last observed values at the time-point that erenumab was stopped for the 
relevant patients, for all the subsequent time-points for those patients. Statistical tests represent paired t-test for MmsHD and Wilcoxon signed 
ranks test for MHD for the 3, 6, 9, and 12 months end points compared to baseline.
Abbreviations: CI, Confidence interval; MHD, monthly total headache days; MmsHD, monthly moderate/severe headache days.
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